×
About 987,808 results

Levodopa‐induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600052/
Postgraduate Medical Journal;

Jun 5th, 2007 - Levodopa is the most effective drug for treating Parkinson's disease. However, long‐term use of levodopa is often complicated by significantly disabling fluctuations and dyskinesias negating its beneficial effects. Younger age of Parkinson's disease onset, disease severity, and high levodopa dose increase the risk of development of levodopa‐induced dyskinesias (LID). The underlying mechanisms f...

High serum cystatin C levels in juvenile myelomonocytic leukemia patients without abnor...
https://doi.org/10.1007/s00467-021-05418-9 10.2174/18715206113139990092 10.1007/s00467-004-1548-3 10.1002/pbc.20581 10.1002/pbc.23119 10.1016/j.lfs.2018.04.013 10.1046/j.1365-2141.1999.01645.x 10.1046/j.1365-2141.2003.04361.x 10.1007/s10157-013-0856-y 10.1007/s10157-013-0910-9 10.1007/s10157-014-1015-9 10.1046/j.1523-1755.2003.00925.x 10.1016/S0009-8981(00)00298-9 10.1038/nrc4027 10.1016/j.imlet.2018.01.006 10.1016/j.blre.2020.100652 10.1007/s00467-018-4087-z 10.2152/jmi.65.231 10.3390/scipharm85010009 10.1080/16078454.2020.1850973 10.1097/MNM.0b013e328360d929 10.1016/j.plabm.2017.05.005 10.1002/pbc.28747 10.1038/icb.2014.121
Pediatric Nephrology (Berlin, Germany); Shimabukuro W, Hamada S et. al.

Jan 22nd, 2022 - In pediatric cancer patients, the estimated glomerular filtration rate based on serum cystatin C (CysC) was reported to be suitable for estimating kidney function because of low serum creatinine (Cr) and high serum β2-microglobulin. Recently, however, serum CysC levels have been reported to be elevated in some cancer patients other than those with juvenile myelomonocytic leukemia (JMML), regard...

Optimization of Spray-Drying Process Parameters to Study Anti-Sticking Effect of Hydrox...
https://doi.org/10.1208/s12249-022-02215-x 10.1016/j.jconrel.2017.11.005 10.1016/j.jfoodeng.2009.01.022 10.3168/jds.2015-10447 10.1016/j.foodres.2012.05.025 10.1016/j.lwt.2016.04.033 10.1016/j.cherd.2015.10.009 10.1016/j.ijbiomac.2019.04.160 10.1111/1750-3841.13970 10.1080/07373937.2013.843543 10.1016/j.ijpharm.2015.03.036 10.1080/10408398.2012.672939 10.1080/07373937.2018.1553181 10.1080/07373939708917253 10.1016/j.ijpharm.2015.06.006 10.1016/j.ejpb.2004.10.002 10.1016/j.foodhyd.2010.07.021 10.1016/j.ejpb.2004.10.002 10.3390/foods9111707 10.1007/s11947-018-2115-4 10.1016/j.lwt.2016.08.055 10.1146/annurev-chembioeng-091720-034106 10.1016/j.ijpharm.2021.120731
AAPS PharmSciTech; Cheng H, Lu C et. al.

Jan 22nd, 2022 - To prevent the sticking of Corni fructus extract (CFE) during spray drying, the anti-sticking effects of different excipients were compared. Hydroxypropyl methylcellulose (HPMC)-VLV showed a higher powder yield at a lower dosage (8% of total solids), and a lower solution viscosity, compared with HPMC-E5. Therefore, HPMC-VLV is a more effective excipient for reducing CFE sticking during spray dr...

Safety, Pharmacokinetics and Pharmacodynamics of DS-1040, in Combination with Thrombect...
https://doi.org/10.1007/s40261-021-01112-8 10.1097/CCM.0000000000004597 10.1016/s0140-6736(16)00163-x 10.3390/ijms18122669 10.1161/STROKEAHA.119.026228 10.1161/STROKEAHA.118.021685 10.1136/neurintsurg-2013-010895.rep 10.1056/NEJMoa1415061 10.1016/j.thromres.2018.06.010 10.1111/jth.13658 10.1002/jcph.1474 10.3174/ajnr.A0843 10.1016/j.jstrokecerebrovasdis.2015.12.022 10.1161/STR.0000000000000158 10.1016/s0140-6736(19)31053-0 10.1161/01.STR.0000257304.21967.ba 10.1177/2396987319832140 10.1161/STR.0000000000000211 10.1111/j.1538-7836.2009.03596.x 10.1111/jth.12216 10.1124/jpet.103.062729 10.1160/TH06-09-0552 10.1160/TH06-09-0551
Clinical Drug Investigation; Sakai N, Takeuchi M et. al.

Jan 22nd, 2022 - DS-1040 is a novel inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor that may have therapeutic potential in thromboembolic diseases, such as acute ischemic stroke (AIS) or pulmonary embolism. We undertook a Phase I clinical trial to investigate the safety, pharmacokinetics, and pharmacodynamics of DS-1040 in Japanese patients who were eligible for thrombectomy follo...

Efficacy of adding pain neuroscience education to a multimodal treatment in fibromyalgi...
https://doi.org/10.1111/1756-185X.14293
International Journal of Rheumatic Diseases; Saracoglu I, Akin E et. al.

Jan 22nd, 2022 - The aim of this study was to investigate whether adding pain neuroscience education (PNE) to a multimodal approach has additional benefits in patients with fibromyalgia (FM). The methodology of this study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The methods and strategies applied in the study were registered in PROSPERO ...

Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B...
https://doi.org/10.1007/s00228-021-03253-3 10.1182/blood-2017-10-813493 10.1182/bloodadvances.2019000767 10.1182/blood.2020007512 10.1158/1078-0432.CCR-19-0711 10.1080/14712598.2020.1776255 10.1186/s13045-021-01097-z 10.1016/S1470-2045(21)00139-X 10.1001/jamadermatol.2020.0208
European Journal of Clinical Pharmacology; Xu B

Jan 22nd, 2022 - Diffuse large B-cell lymphoma (DLBCL) is the most common type of Non-Hodgkin's lymphoma in the United States, with approximately 40% of first-line DLBCL chemoimmunotherapy attempts failing. The FDA approved a new type of antibody-drug conjugate (ADC), Zynlonta (loncastuximab tesirine), once called ADCT-402, on April 23, 2021, for relapsed or refractory (R/R) DLBCL. Loncastuximab tesirine compri...

Single dose versus low dose rituximab in corticosteroid-resistant or relapsed ITP: a mu...
https://doi.org/10.1002/ajh.26473
American Journal of Hematology; Ni X, Li D et. al.

Jan 21st, 2022 - Primary immune thrombocytopenia (ITP) is an autoimmune bleeding disorder, in which rituximab (RTX) induces the best long-term effect among recommended second-line treatments. Nevertheless, the optimal regimen of rituximab remains unclear. We herein conducted a prospective, multicenter, open-label, randomized controlled trial to compare the efficacy and safety of rituximab at two different dosag...

Comparison of vancomycin clearance between augmented renal clearance and normal renal f...
https://doi.org/10.1002/jcph.2029
Journal of Clinical Pharmacology; Huang GM, Qiu Y et. al.

Jan 21st, 2022 - Augmented renal clearance show a super-renal function with enhanced renal perfusion and glomerular hyperfiltration in many critically ill infants. The study were to compare vancomycin clearance (CL) between augmented renal clearance and normal renal function critically ill infants and to optimize the vancomycin dosage. Data were retrospectively obtained from intensive care unit infants. Populat...

Aspirin in the prevention of preeclampsia: A protocol for systematic review and meta an...
https://doi.org/10.1097/MD.0000000000027916
Medicine Mkhize PZ, Phoswa WN et. al.

Jan 21st, 2022 - Aspirin is widely used to prevent pregnancy related vascular disorders such as preeclampsia (PE), intrauterine growth restriction and maternal disorders. However, the indications for the use of aspirin during pregnancy is currently controversial because the dosage of aspirin used and the sample sizes in various studies differ considerably. Furthermore, women of African ancestry are more likely ...

Impact of Diquafosol Ophthalmic Solution on Tear Film and Dry Eye Symptom in Type 2 Dia...
https://doi.org/10.1089/jop.2021.0083
Journal of Ocular Pharmacology and Therapeutics : the Off... Zhang Q, Zhang H et. al.

Jan 21st, 2022 - Background: Diquafosol ophthalmic solution (DQS) stimulates P2Y2 receptors on the ocular surface, which enhances mucin secretion from goblet cells. Therefore, tear film stability and hydration of the ocular surface can be achieved independent from lacrimal gland function. Methods: This prospective, open-label pilot study included 60 eyes of 30 diabetic patients diagnosed with dry eye disease (D...

Comparative efficacy and acceptability of cholinesterase inhibitors and memantine based...
https://doi.org/10.2174/1567205019666220120112301
Current Alzheimer Research; Shi X, Ren G et. al.

Jan 21st, 2022 - Considering the lack of direct comparison between cholinesterase inhibitors and memantine in patients with vascular cognitive impairment (VCI), determining how to choose the best treatment plan remains inconclusive. Hence, we conducted the network meta-analysis to compare the efficacy and acceptability of these drugs. PubMed, the Cochrane Central Register of Controlled Trials, Embase and Web of...

Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depr...
https://doi.org/10.1192/bjp.2021.165
The British Journal of Psychiatry : the Journal of Mental... Furukawa Y, Hamza T et. al.

Jan 21st, 2022 - Aripiprazole augmentation is proven effective for antidepressant-refractory depression, but its licensed dose range is wide and optimal dosage remains unclear. To find the optimal dosage of aripiprazole augmentation. Multiple electronic databases were searched (from inception to 16 February 2021) to identify all assessor-masked randomised controlled trials evaluating aripiprazole augmentation t...

Microfluidic spinning of fucoxanthin-loaded nanofibers for enhancing antioxidation and ...
https://doi.org/10.1039/d1fo03766h
Food & Function; Li J, Li Y et. al.

Jan 21st, 2022 - Fruit juice is one of the most popular drinks, which requires strict processing conditions to ensure its quality, especially to prevent enzymatic browning and turbidity loss. In this work, a new strategy for the preparation of composite nanofibers for juice clarification and anti-browning control was proposed. The strategy used microfluidic spinning to combine Fucoxanthin (Fx), hydroxypropyl-γ-...

Bacteriophages Combined With Subtherapeutic Doses of Flucloxacillin Act Synergistically...
https://doi.org/10.1161/JAHA.121.023080
Journal of the American Heart Association; Save J, Que YA et. al.

Jan 20th, 2022 - Background The potential of phage therapy for the treatment of endovascular Staphylococcus aureus infections remains to be evaluated. Methods and Results The efficacy of a phage cocktail combining Herelleviridae phage vB_SauH_2002 and Podoviriae phage 66 was evaluated against a methicillin-sensitive S. aureus strain in vitro and in vivo in a rodent model of experimental endocarditis. Six hours ...

Dose-dependent effect of myelin oligodendrocyte glycoprotein on visual function and opt...
https://doi.org/10.1002/jnr.25007
Journal of Neuroscience Research; Castoldi V, Marenna S et. al.

Jan 20th, 2022 - Female Dark Agouti rats were immunized with increasing doses of myelin oligodendrocyte glycoprotein (MOG) to develop experimental autoimmune encephalomyelitis (EAE), a preclinical model of multiple sclerosis. Typical EAE motor impairments were assessed daily and noninvasive visual evoked potentials (VEPs) were recorded at baseline and 5 weeks after immunization, with final histopathology of opt...

Pharmacokinetic/pharmacodynamic simulations of cost-effective dosage regimens of ceftol...
https://doi.org/10.1128/AAC.02104-21
Antimicrobial Agents and Chemotherapy; Dheyriat L, Bourguignon L et. al.

Jan 19th, 2022 - The pharmacokinetics of ceftolozane/tazobactam (TOL/TAZ) and ceftazidime/avibactam (CEF/AVI) is influenced by renal function. Application of recommended dosages in patients with renal impairment require to use fractions of the full dose, as only one dosage is available for both antibiotics. The objective of this study was to evaluate the adequacy of alternative dosage regimens based on the full...

Countries Manufacturing Pharmaceuticals for the US Market: A 10-Year Analysis of Public...
https://doi.org/10.1177/10600280211069540
The Annals of Pharmacotherapy; Hatton RC, Leighton G et. al.

Jan 19th, 2022 - Concerns about strategic supplies and quality have increased the scrutiny of the countries where US pharmaceuticals are made. To examine the locations of manufacturers of brand name, biological, and generic drugs over 10 years. This longitudinal descriptive study used publicly available data from US government Web sites, including the Food and Drug Administration (FDA) Drug Establishments list,...

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced ...
https://doi.org/10.1080/09537104.2022.2026910
Platelets Gao Y, Liu Q et. al.

Jan 19th, 2022 - Chemotherapy-induced thrombocytopenia (CIT) is a common complication in cancer patients, especially after multiple cycles of chemotherapy, which leads to the delayed treatment or reduced dosage. The treatment of CIT is limited for refractory and severe cases. Herein we reported a single-center study of avatrombopag, a type of thrombopoietin receptor agonist (TPO-RA), for the treatment of severe...

Progranulin as a therapeutic target in neurodegenerative diseases.
https://doi.org/10.1016/j.tips.2021.11.015
Trends in Pharmacological Sciences; Rhinn H, Tatton N et. al.

Jan 19th, 2022 - Progranulin (PGRN, encoded by the GRN gene) plays a key role in the development, survival, function, and maintenance of neurons and microglia in the mammalian brain. It regulates lysosomal biogenesis, inflammation, repair, stress response, and aging. GRN loss-of-function mutations cause neuronal ceroid lipofuscinosis or frontotemporal dementia-GRN (FTD-GRN) in a gene dosage-dependent manner. Mu...

Clinical outcomes of individualized busulfan-dosing in hematopoietic stem cell transpla...
https://doi.org/10.1038/s41409-021-01545-x 10.1016/j.beha.2006.09.004 10.1038/s41409-018-0281-7 10.1016/j.bbmt.2008.11.022 10.1097/FTD.0000000000000131 10.1097/FTD.0b013e3182a04fc7 10.1016/S2352-3026(16)30114-4 10.1038/sj.bmt.1703264 10.1038/sj.bmt.1704446 10.1200/JCO.1988.6.10.1562 10.7326/0003-4819-118-4-199302150-00003 10.1038/sj.bmt.1701899 10.1016/j.bbmt.2011.11.025 10.1200/JCO.2012.44.3523 10.1016/j.bbmt.2018.06.034 10.1016/j.bbmt.2014.09.013 10.1002/ajh.24734 10.1016/j.bbmt.2007.10.028 10.1111/j.1399-3046.2011.01529.x 10.1016/j.bbmt.2006.10.026 10.1532/IJH97.07013 10.1002/pbc.22227 10.1038/bmt.2015.218 10.1007/s00280-007-0455-2 10.1158/1078-0432.CCR-11-0074 10.12659/AOT.889933 10.1097/FTD.0b013e31829dc940 10.1182/blood-2010-01-265405
Bone Marrow Transplantation; Shao DF, Li JH et. al.

Jan 19th, 2022 - To identify relationships between busulfan (Bu) exposure and outcomes of a cohort pediatric patients receiving hematopoietic stem cell transplantation (HSCT), along with a targeted busulfan-based conditioning regimen. We retrospectively evaluated targeted busulfan concentrations in 53 pediatric patients (age 0.4-16 years) who received busulfan 4 times daily according to recommended weight-based...